Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Transitional Cell × dactolisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neuroectodermal Tumors, Primitive 2 Uterine Neoplasms 1 Tuberous Sclerosis 1 Perivascular Epithelioid Cell Neoplasms 1 Neuroendocrine Tumors 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Breast Neoplasms 1 Angiomyolipoma 1

Interventions

pembrolizumab 21 Gemcitabine 21 Nivolumab 13 Cisplatin 13 atezolizumab 12 avelumab 11 Carboplatin 10 Docetaxel 9 enfortumab vedotin 7 Paclitaxel 7 durvalumab 6 Magnetic Resonance Spectroscopy 6 Ipilimumab 6 pemigatinib 5 Specimen Handling 5 vinflunine 4 toripalimab 4 sacituzumab govitecan 4 cabozantinib 4 Taxes 4 Pemetrexed 3 Injections 3 Everolimus 3 Albumin-Bound Paclitaxel 3 tislelizumab 2 sapanisertib 2 disitamab vedotin 2 cabazitaxel 2 Trastuzumab 2 Standard of Care 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01856101 2019-04-10

BEZ235

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 2 Terminated

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡